HCV kinetic models and their implications in drug development

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 4, 2015, Pages 231-242

  Nguyen, T H T ^a   Guedj, J ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; RIBAVIRIN; TELAPREVIR;

CELL DIFFERENTIATION; CELL MIGRATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS C VIRUS; HUMAN; KINETICS; LIVER CELL; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEADY STATE; VIRUS KINETICS; VIRUS LOAD;

EID: 84936771795     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.28     Document Type: Review

References (90)

1. Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., &, Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342 (2013).
2. Lawitz, E., et al,. High concordance of SVR4, SVR12, and SVR24 in patients with HCV infection who have received treatment with sofosbuvir. J. Hepatol. 58, S348 (2013).
3. Carrion, A.F., Gutierrez, J., &, Martin, P., New antiviral agents for the treatment of hepatitis C: ABT-450. Expert Opin. Pharmacother. 15, 711-716 (2014).
4. Zhu, Y., &, Chen, S., Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J. Gastroenterol. WJG 19, 8963-8973 (2013).
5. Manns, M.P., et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
6. Fried, M.W., et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
7. Jacobson, I.M., et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
8. Poordad, F., et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
9. Kowdley, K.V., et al,. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370, 1879-1888 (2014).
10. Everson, G.T., et al,. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146, 420-429 (2014).
11. Kohli, A., et al,. Combination oral, hepatitis C antiviral therapy for 6 or 12 weeks: Results of the SYNERGY Trial. 21st CROI Abstr 27LB (2014).
12. Gane, E.J., et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44 (2013).
13. Afdhal, N., et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889-1898 (2014).
14. Gentile, I., et al,. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: The dawn of the a new era. Rev. Recent Clin. Trials 9, 1-7 (2014).
15. Neumann, A.U., et al,. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103-107 (1998).
16. Dahari, H., Ribeiro, R.M., &, Perelson, A.S., Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46, 16-21 (2007).
17. Herrmann, E., Lee, J.-H., Marinos, G., Modi, M., &, Zeuzem, S., Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37, 1351-1358 (2003).
18. Dahari, H., Lo, A., Ribeiro, R.M., &, Perelson, A.S., Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J. Theor. Biol. 247, 371-381 (2007).
19. Guedj, J., Bazzoli, C., Neumann, A.U., &, Mentré, F., Design evaluation and optimization for models of hepatitis C viral dynamics. Stat. Med. 30, 1045-1056 (2011).
20. Graw, F., et al,. Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. PLoS Comput. Biol. 10, e1003934 (2014).
21. Kandathil, A.J., et al,. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 145, 1404-1413.e10 (2013).
22. Pawlotsky, J.-M., et al,. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126, 703-714 (2004).
23. Rotman, Y., et al,. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 63, 161-169 (2014).
24. Mihm, U., et al,. Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. J. Viral Hepat. 21, 42-52 (2014).
25. Layden-Almer, J.E., Ribeiro, R.M., Wiley, T., Perelson, A.S., &, Layden, T.J., Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37, 1343-1350 (2003).
26. Dixit, N.M., Layden-Almer, J.E., Layden, T.J., &, Perelson, A.S., Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922-924 (2004).
27. Snoeck, E., et al,. A comprehensive hepatitis C viral kinetic model explaining cure. Clin. Pharmacol. Ther. 87, 706-713 (2010).
28. Feld, J.J., et al,. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 139, 154-162.e4 (2010).
29. Hézode, C., et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).
30. McHutchison, J.G., et al,. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292-1303 (2010).
31. Ferenci, P., et al,. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370, 1983-1992 (2014).
32. Thomas, E., et al,. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53, 32-41 (2011).
33. Steimer, J.L., Mallet, A., Golmard, J.L., &, Boisvieux, J.F., Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab. Rev. 15, 265-292 (1984).
34. Samson, A., Lavielle, M., &, Mentré, F., Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput. Stat. Data Anal. 51, 1562-1574 (2006).
35. Beal, S.L., Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28, 481-504 (2001).
36. Yang, S., &, Roger, J., Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data. Pharm. Stat. 9, 313-330 (2010).
37. McGivern, D.R., et al,. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147, 453-462.e7 (2014).
38. Shudo, E., Ribeiro, R.M., &, Perelson, A.S., Modeling hepatitis C virus kinetics under therapy using pharmacokinetic and pharmacodynamic information. Expert Opin. Drug Metab. Toxicol. 5, 321-332 (2009).
39. Sypsa, V., &, Hatzakis, A., Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials. Stat. Med. 27, 6505-6521 (2008).
40. Nguyen, T.H.T., Mentré, F., Yu, J., Levi, M., &, Guedj, J., A pharmacokinetic-viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on hepatitis C virologic response. Clin. Pharmacol. Ther. (in press).
41. Laouénan, C., et al,. Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients (ANRS CO20-CUPIC). Antimicrob. Agents Chemother. (2014). doi: 10.1128/AAC.02611-14
42. Zhang, L., Beal, S.L., &, Sheiner, L.B., Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J. Pharmacokinet. Pharmacodyn. 30, 387-404 (2003).
43. Lacroix, B.D., Friberg, L.E., &, Karlsson, M.O., Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. J. Pharmacokinet. Pharmacodyn. 39, 177-193 (2012).
44. Tod, M., Evaluation of drugs in pediatrics using K-PD models: perspectives. Fundam. Clin. Pharmacol. 22, 589-594 (2008).
45. Conway, J.M., &, Perelson, A.S., A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis. PLoS Comput. Biol. 10, e1003769 (2014).
46. Guedj, J., Dahari, H., Shudo, E., Smith, P., &, Perelson, A.S., Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55, 1030-1037 (2012).
47. Guedj, J., et al,. Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir. Ther. 19, 211-220 (2014).
48. Ma, H., et al,. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor β-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine (psi-6130) and identification of a novel active 5′-triphosphate species. J. Biol. Chem. 282, 29812-29820 (2007).
49. Guedj, J., Dahari, H., Pohl, R.T., Ferenci, P., &, Perelson, A.S., Understanding silibinin's modes of action against HCV using viral kinetic modeling. J. Hepatol. 56, 1019-1024 (2012).
50. Dahari, H., Ribeiro, R.M., Rice, C.M., &, Perelson, A.S., Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J. Virol. 81, 750-760 (2007).
51. Binder, M., et al,. Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle. PLoS Pathog. 9, e1003561 (2013).
52. Dahari, H., Sainz, B. Jr., Perelson, A.S., &, Uprichard, S.L., Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J. Virol. 83, 6383-6390 (2009).
53. Ivanisenko, N.V., et al,. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants. PloS One 9, e91502 (2014).
54. Reddy, M.B., et al,. Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob. Agents Chemother. 56, 3144-3156 (2012).
55. Kieffer, T.L., et al,. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639 (2007).
56. Ribeiro, R.M., et al,. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 8, e1002881 (2012).
57. Cuevas, J.M., González-Candelas, F., Moya, A., &, Sanjuán, R., Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83, 5760-5764 (2009).
58. Rong, L., Dahari, H., Ribeiro, R.M., &, Perelson, A.S., Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2, 30ra32 (2010).
59. Adiwijaya, B.S., et al,. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput. Biol. 6, e1000745 (2010).
60. Adiwijaya, B.S., et al,. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput. Biol. 8, e1002339 (2012).
61. Ferenci, P., et al,. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135, 451-458 (2008).
62. Mangia, A., et al,. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J. Hepatol. 53, 1000-1005 (2010).
63. Lindh, M., et al,. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J. Clin. Microbiol. 45, 2439-2445 (2007).
64. Neumann, A.U., et al,. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. Liver Int. 29, 1350-1355 (2009).
65. Guedj, J., &, Perelson, A.S., Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53, 1801-1808 (2011).
66. Gane, E.J., et al,. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467-1475 (2010).
67. Gane, E.J., et al,. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int. Off. J. Int. Assoc. Study Liver (2014). doi: 10.1111/liv.12588
68. Herrmann, E., et al,. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir. Ther. 11, 371-376 (2006).
69. Reesink, H.W., et al,. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138, 913-921 (2010).
70. Guedj, J., et al,. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. U. S. A. 110, 3991-3996 (2013).
71. Rong, L., et al,. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput. Biol. 9, e1002959 (2013).
72. Lawitz, E.J., et al,. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J. Hepatol. 57, 24-31 (2012).
73. Guedj, J., &, Neumann, A.U., Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J. Theor. Biol. 267, 330-340 (2010).
74. Carloni, G., Crema, A., Valli, M.B., Ponzetto, A., &, Clementi, M., HCV infection by cell-to-cell transmission: Choice or necessity? Curr. Mol. Med. 12, 83-95 (2012).
75. Vigneaux, P., Extending monolix to use models with partial differential equations Paul Vigneaux (1), Violaine Louvet (2), Emmanuel Grenier (1)(1) ENS de LYON & INRIA Numed;(2) Université de LYON & INRIA Numed.
76. Pearson, J.E., Krapivsky, P., &, Perelson, A.S., Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput. Biol. 7, e1001058 (2011).
77. Dahari, H., et al,. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int. (2014) doi: 10.1111/liv.12692.
78. Guedj, J., &, Nguyen, T.H.T., Can we use viral kinetic models to individualize treatment? Liver Int. (2014) doi: 10.1111/liv.12736.
79. Nguyen, T.H.T., Guedj, J., Yu, J., Levi, M., &, Mentré, F., Influence of a priori information, designs, and undetectable data on individual parameters estimation and prediction of hepatitis C treatment outcome. CPT Pharmacomet. Syst. Pharmacol. 2, e56 (2013).
80. DeBroy, S., Bolker, B.M., &, Martcheva, M., Bistability and long-term cure in a within-host model of hepatitis C. J. Biol. Syst. 19, 533-550 (2011).
81. Greco, W.R., Bravo, G., &, Parsons, J.C., The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385 (1995).
82. Lee, J.J., Kong, M., Ayers, G., &, Lotan, R., Interaction index and different methods for determining drug interaction in combination therapy. J. Biopharm. Stat. 17, 461-480 (2007).
83. Rong, L., Ribeiro, R.M., &, Perelson, A.S., Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull. Math. Biol. 74, 1789-1817 (2012).
84. Snoeck, E., Wade, J.R., Duff, F., Lamb, M., &, Jorga, K., Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br. J. Clin. Pharmacol. 62, 699-709 (2006).
85. Laouénan, C., et al,. A model-based illustrative exploratory approach to optimize the dosing of Peg-IFN and ribavirin in cirrhotic hepatitis C infected patients treated with triple therapy (ANRS CO20-CUPIC). CPT Pharmacomet. Syst. Pharmacol. (in press).
86. Sidharthan, S., et al,. Predicting response to all-oral directly acting antiviral therapy for hepatitis C using results of Roche and Abbott HCV viral load assays. 23rd APASL 8, Abstr 865, S227-228 (2014).
87. Matsuura, K., et al,. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J. Clin. Microbiol. 47, 385-389 (2009).
88. Morishima, C., et al,. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 44, 360-367 (2006).
89. Bortoletto, G., et al,. Comparable performance of TMA and real-time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 50, 217-220 (2011).
90. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment (Draft). Revision 1, (2013).